Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults over 18 years old, of any gender.
• People who are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests and procedures, confirmed by signing a consent form.
• People who have been diagnosed with liver cancer (hepatocellular carcinoma), confirmed by tissue sample, cell sample, or characteristic findings on imaging scans (ultrasound, CT, or MRI) combined with blood tests.
• People who have at least one measurable liver cancer lesion, as assessed using a specific measurement method called mRECIST.
• People who have a blood clot caused by the tumour in a branch of the portal vein (a major liver blood vessel) that a specialist medical team has determined may be removable through surgery.
• People with no history of any other type of cancer.
• People who have not previously received any treatment for their liver cancer, including targeted therapy, chemotherapy, surgery, interventional procedures, or radiotherapy.
• People expected to live for at least 3 months.
• People who are generally able to carry out daily activities with no or minimal limitations, based on a standard medical scale (ECOG score of 0 or 1).
• People whose liver is functioning at a healthy enough level, based on a scoring system called Child-Pugh A (score of 6 or below).
• People whose kidneys, liver, and blood cell counts fall within acceptable ranges based on specific laboratory test results (confirm with trial site for exact values).
• Women of childbearing potential must have a negative pregnancy blood test within 3 days before starting the study treatment and must agree to use an effective form of contraception during the study and for 3 months after the last dose.
• Men with partners who could become pregnant must either have had a surgical procedure to prevent conception or agree to use effective contraception during the study and for 3 months after the last dose.

Who may not be able to join:

• People who have previously received interventional procedures, immunotherapy, chemotherapy, or targeted therapy for their cancer.
• People whose cancer has spread to other parts of the body (distant metastasis), or whose tumour clot involves the main portal vein (classified as Vp4).
• People with severe fluid build-up in the abdomen (ascites) that does not respond to treatment, or with a condition called hepatic encephalopathy (brain problems caused by liver failure).
• People who have another active cancer in a different part of the body.
• People whose kidney, liver, or blood function is too poor to safely tolerate the treatment.
• People with serious heart conditions, including significant irregular heartbeat, reduced blood supply to the heart, severe heart block, heart failure, or severe heart valve disease.
• People with severe bone marrow failure.
• People currently being treated for an active autoimmune disease (a condition where the immune system attacks the body's own tissues).
• People who have taken part in another cancer clinical trial within the last 3 months.
• People with a history of active tuberculosis or ongoing infections that cannot be controlled.
• People who are pregnant or breastfeeding.
• People with a history of HIV infection.
• People who the trial investigators believe would not be suitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.